How many rheumatologists are managing psoriasis themselves? Or dermatologists managing arthritis themselves? Survey shows <50% rheum collaborate with derm Need updated EMRs and additional education Abs#1502 @RheumNow #ACR22 https://t.co/1okhxFAbUS

⚡️PRESTO⚡️ 📈PsA prediction tool in psoriasis Risk of PsA at 1yr ⬆️: 👉younger 👉male 👉FHx Psoriasis 👉back stiffness 👉stiffness level 👉nail pitting 👉biologic use 👉⬆️ pain and global health (AUC 72.3,95%CI 65.5,79.1) #ACR22 @RheumNow Abst#1612

Prevalence of uveitis in patients with PsA was about 5%. Uveitis rate decreased w/ anti-TNFα monoclonal antibodies and increased w/ ETN and SECU. Abs 1159 #ACR22 @RheumNow https://t.co/BtHMQ6apNI https://t.co/uZEYVQdiOU

• Uveitis in Psoriatic Arthritis: Study of 406 Patients in a Single University Ce…

Ab1486 #ACR22 @Keith_Colaco: Disease-specific CV Risk Prediction Model for PsO, PsA Prediction base model w only traditional CV risks excellent (AUC 85.5) Expanded model w damaged jts did not improve risk discrimination @Rheumnow https://t.co/DMlOreW9zK

Ab1508 #ACR22 Enthesitis on PET/CT 20 untreated PsA pts w/ total body PET/CT All 20 (100%) pts had entheseal inflammation 127/543 (~1/4) entheses showed inflammation @RheumNow https://t.co/OQCBWW70bt

Does Bimekizumab, anti-IL17F, work in PsA? #ACR22 @RheumNow Abstract #L02 💊Phase 3, randomized, placebo-controlled study 💉Biologic naive patients ✋ Week 52: 53-54% BKZ groups achieved ACR502 (v. 50% in TNFi) 📍benefits sustained to week 52 🛑No new safety signals

FOREMOST results: Early oligoarticular PsA pts experienced high disease burden/decreased QoL. Small joint involvement, although less commonly seen in oligoarticular PsA, was the most frequently observed pattern. Abs 1018 #ACR22 @RheumNow https://t.co/wBldKM9MTq https://t.co/qOVZd8aTyR

• Characterization of Joint Distribution and Disease Burden in Patients with Earl…

Post hoc analysis of 3 PsA/SPA trials: no effect of tobacco 🚬 on TOFA efficacy But numerically higher TEAEs Contrasting w/ data from real world TNF Interesting data but small sample size & events N https://t.co/gv8uvcThMD Abs#1036 #ACR22 @Rheumnow https://t.co/HCJT0XF1tg

• Efficacy and Safety of Tofacitinib in Patients with Psoriatic Arthritis or Anky…

DANBIO registry: 1600+ pts RA, AxSpA, PsA Infiximab biosimilar to biosimilar switch (CT-P13 -> GP1111) Maintenance at 1yr: >80% > withdrawal in original IFX naive, but higher BL DA Do second time switchers do better because of past switch experience? Abs#1112 #ACR22 @RheumNow https://t.co/IgjhGLVESz